Who
Eddie Joe Sullivan
President
Company insider
Files Form 4 as: President, SAB Biotherapeutics.
In numbers
- Trades disclosed
- 19
- Buys
- 2
- Sells
- 0
- Bought
- $12K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 Oct 2021
- Last trade
- 3 Feb 2026
- Last filed
- 5 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Feb 2026filed 5 Feb 2026 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000,000 at $0.00 | filing |
| 26 Aug 2025filed 28 Aug 2025 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000,000 at $0.00 | filing |
| 15 Jul 2024filed 17 Jul 2024 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,528 at $0.00 | filing |
| 15 Jul 2024filed 17 Jul 2024 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,447 at $0.00 | filing |
| 21 Feb 2024filed 23 Feb 2024 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,000 at $0.00 | filing |
| 7 Dec 2023filed 8 Dec 2023 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $1,5311,740 at $0.88 | filing |
| 14 Mar 2023filed 16 Mar 2023 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
| 13 Sep 2022filed 15 Sep 2022 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 7 Sep 2022filed 8 Sep 2022 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $10K14,000 at $0.74 | filing |
| 16 Mar 2022filed 18 Mar 2022 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,218 at $0.00 | filing |
| 22 Oct 2021filed 26 Oct 2021 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,106,361 | filing |
| 22 Oct 2021filed 26 Oct 2021 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —139,585 | filing |
| 22 Oct 2021filed 26 Oct 2021 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —162,850 | filing |
| 22 Oct 2021filed 26 Oct 2021 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —162,850 | filing |
| 22 Oct 2021filed 26 Oct 2021 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,264 | filing |
| 22 Oct 2021filed 26 Oct 2021 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —197,374 | filing |
| 22 Oct 2021filed 26 Oct 2021 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —5,213,764 | filing |
| 7 Oct 2021filed 26 Oct 2021 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code A | $28K2,800 at $10.07 | filing |
News
No headline names them, or the companies they trade most, lately.